Acute myeloid leukemia following a myeloproliferative neoplasm: Clinical characteristics, genetic features and effects of therapy Journal Article
| Authors: | Heaney, M. L.; Soriano, G. |
| Article Title: | Acute myeloid leukemia following a myeloproliferative neoplasm: Clinical characteristics, genetic features and effects of therapy |
| Abstract: | Acute myeloid leukemia (AML) is an uncommon, but often deadly complication of myeloproliferative neoplasms (MPN). Post-MPN AML usually occurs years after the initial MPN diagnosis with an average age of onset between 64 and 68 years. Chromosome abnormalities are common and many patients have cytogenetic changes that are associated with poor risk features. Post-MPN AML is characterized by acquired somatic gene mutations, but, interestingly, mutations thought to have an etiologic role in the MPN, such as JAK2V617F, are sometimes absent in the AML clone. Conventional AML-style treatment appears to have limited efficacy, although when coupled to allogeneic stem cell transplantation, some patients have long-term survival. Less-intensive therapies such as hypomethylating agents and the JAK inhibitor, ruxolitinib, may be effective in some patients. New treatments have prompted efforts to characterize therapeutic responses better. © 2013 Springer Science+Business Media New York. |
| Keywords: | signal transduction; cancer chemotherapy; cancer survival; treatment response; myeloproliferative disorders; acute granulocytic leukemia; somatic mutation; gene deletion; genetics; myeloproliferative disorder; leukemia, myeloid, acute; hydroxyurea; janus kinase 2; allogeneic stem cell transplantation; clinical feature; drug efficacy; antineoplastic agents; cancer incidence; gene overexpression; multiple cycle treatment; classification; cytogenetics; stem cell transplantation; molecular cloning; chromosome aberration; gene conversion; hematologic neoplasms; response; 5 aza 2' deoxycytidine; bcr abl protein; onset age; karyotype; azacitidine; myeloproliferative neoplasm; leukemia remission; phase 2 clinical trial (topic); acute myeloid leukemia; clonal; phlebotomy; janus kinases; long term survival; hypomethylating; ruxolitinib; blast phase; jak inhibitor |
| Journal Title: | Current Hematologic Malignancy Reports |
| Volume: | 8 |
| Issue: | 2 |
| ISSN: | 1558-8211 |
| Publisher: | Springer |
| Date Published: | 2013-06-01 |
| Start Page: | 116 |
| End Page: | 122 |
| Language: | English |
| DOI: | 10.1007/s11899-013-0154-5 |
| PROVIDER: | scopus |
| PUBMED: | 23572311 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 July 2013" - "Source: Scopus" |
